Type I interferon signaling, regulation and gene stimulation in chronic virus infection
Open accessThe DOI matches its Crossref record; 35 of the 35 references it cites were found in a registry or an index.
Abstract
Type I Interferons (IFN-I) mediate numerous immune interactions during viral infections, from the establishment of an antiviral state to invoking and regulating innate and adaptive immune cells that eliminate infection. While continuous IFN-I signaling plays critical roles in limiting virus replication during both acute and chronic infections, sustained IFN-I signaling also leads to chronic immune activation, inflammation and, consequently, immune exhaustion and dysfunction. Thus, an understanding of the balance between the desirable and deleterious effects of chronic IFN-I signaling will inform our quest for IFN-based therapies for chronic viral infections as well as other chronic diseases, including cancer. As such the factors involved in induction, propagation and regulation of IFN-I signaling, from the initial sensing of viral nucleotides within the cell to regulatory downstream signaling factors and resulting IFN-stimulated genes (ISGs) have received significant research attention. This review summarizes recent work on IFN-I signaling in chronic infections, and provides an update on therapeutic approaches being considered to counter such infections.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Pattern Recognition Receptors and Inflammation
Takeuchi, O., & Akira, S. (2010) · Cell · doi:10.1016/j.cell.2010.01.022 · Cited by 8,895
Primary, Adaptive, and Acquired Resistance to Cancer Immunotherapy
Sharma, P., Hu-Lieskovan, S., Wargo, J. A., & Ribas, A. (2017) · Cell · doi:10.1016/j.cell.2017.01.017 · Cited by 5,588
Molecular and cellular insights into T cell exhaustion
Wherry, E. J., & Kurachi, M. (2015) · Nature Reviews Immunology · doi:10.1038/nri3862 · Cited by 4,652
STING is an endoplasmic reticulum adaptor that facilitates innate immune signalling
Ishikawa, H., & Barber, G. N. (2008) · Nature · doi:10.1038/nature07317 · Cited by 3,576
Virus interference. I. the interferon
Isaacs, A., & Lindenmann, J. (1957) · Proceedings of the Royal Society of London. Series B - Biological Sciences · doi:10.1098/rspb.1957.0048 · Cited by 3,451
Mutations Associated with Acquired Resistance to PD-1 Blockade in Melanoma
Zaretsky, J. M., Garcia-Diaz, A., Shin, D. S., Escuin-Ordinas, H., Hugo, W., Hu-Lieskovan, S., Torrejon, D. Y., Abril-Rodriguez, G., Sandoval, S., Barthly, L., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1604958 · Cited by 3,237
Interferon-stimulated genes: A complex web of host defenses
Schneider, W. M., Chevillotte, M. D., & Rice, C. M. (2014) · Annual Review of Immunology · doi:10.1146/annurev-immunol-032713-120231 · Cited by 3,067
Zelante, T., Iannitti, R. G., Cunha, C., De Luca, A., Giovannini, G., Pieraccini, G., Zecchi, R., D’Angelo, C., Massi-Benedetti, C., Fallarino, F., et al. (2013) · Immunity · doi:10.1016/j.immuni.2013.08.003 · Cited by 2,614 · cited 1×
“IDO for example, catalyses the conversion of tryptophan to kynurenine, which then suppresses immunity by signaling through the aryl hydrocarbon receptor (112).”
BackgroundRadiation and dual checkpoint blockade activate non-redundant immune mechanisms in cancer
Twyman-Saint Victor, C., Rech, A. J., Maity, A., Rengan, R., Pauken, K. E., Stelekati, E., Benci, J. L., Xu, B., Dada, H., Odorizzi, P. M., et al. (2015) · Nature · doi:10.1038/nature14292 · Cited by 2,434
Defining CD8+ T cells that provide the proliferative burst after PD-1 therapy
Im, S. J., Hashimoto, M., Gerner, M. Y., Lee, J., Kissick, H. T., Burger, M. C., Shan, Q., Hale, J. S., Lee, J., Nasti, T. H., et al. (2016) · Nature · doi:10.1038/nature19330 · Cited by 2,070
Mitochondrial DNA stress primes the antiviral innate immune response
West, A. P., Khoury-Hanold, W., Staron, M., Tal, M. C., Pineda, C. M., Lang, S. M., Bestwick, M., Duguay, B. A., Raimundo, N., MacDuff, D. A., et al. (2015) · Nature · doi:10.1038/nature14156 · Cited by 1,975
Phosphorylation of innate immune adaptor proteins MAVS, STING, and TRIF induces IRF3 activation
Liu, S., Cai, X., Wu, J., Cong, Q., Chen, X., Li, T., Du, F., Ren, J., Wu, Y.-T., Grishin, N. V., et al. (2015) · Science · doi:10.1126/science.aaa2630 · Cited by 1,927 · cited 1×
“translocate into the nucleus where they bind to promoter regions of IFNβ and other target genes thereby stimulating IFN-I and pro-inflammatory cytokine gene transcription (10).”
BackgroundMitotic progression following DNA damage enables pattern recognition within micronuclei
Harding, S. M., Benci, J. L., Irianto, J., Discher, D. E., Minn, A. J., & Greenberg, R. A. (2017) · Nature · doi:10.1038/nature23470 · Cited by 1,508
Loss of IFN-γ pathway genes in tumor cells as a mechanism of resistance to anti-CTLA-4 therapy
Gao, J., Shi, L. Z., Zhao, H., Chen, J., Xiong, L., He, Q., Chen, T., Roszik, J., Bernatchez, C., Woodman, S. E., et al. (2016) · Cell · doi:10.1016/j.cell.2016.08.069 · Cited by 1,300
The IRF Family Transcription Factors in Immunity and Oncogenesis
Tamura, T., Yanai, H., Savitsky, D., & Taniguchi, T. (2008) · Annual Review of Immunology · doi:10.1146/annurev.immunol.26.021607.090400 · Cited by 1,259
Tumor Interferon Signaling Regulates a Multigenic Resistance Program to Immune Checkpoint Blockade
Benci, J. L., Xu, B., Qiu, Y., Wu, T. J., Dada, H., Twyman-Saint Victor, C., Cucolo, L., Lee, D. S. M., Pauken, K. E., Huang, A. C., et al. (2016) · Cell · doi:10.1016/j.cell.2016.11.022 · Cited by 1,216
Targeting STING with covalent small-molecule inhibitors
Haag, S. M., Gulen, M. F., Reymond, L., Gibelin, A., Abrami, L., Decout, A., Heymann, M., van der Goot, F. G., Turcatti, G., Behrendt, R., et al. (2018) · Nature · doi:10.1038/s41586-018-0287-8 · Cited by 1,178
In vivo CRISPR screening identifies Ptpn2 as a cancer immunotherapy target
Manguso, R. T., Pope, H. W., Zimmer, M. D., Brown, F. D., Yates, K. B., Miller, B. C., Collins, N. B., Bi, K., LaFleur, M. W., Juneja, V. R., et al. (2017) · Nature · doi:10.1038/nature23270 · Cited by 1,147
Pan-viral specificity of IFN-induced genes reveals new roles for cGAS in innate immunity
Schoggins, J. W., MacDuff, D. A., Imanaka, N., Gainey, M. D., Shrestha, B., Eitson, J. L., Mar, K. B., Richardson, R. B., Ratushny, A. V., Litvak, V., et al. (2014) · Nature · doi:10.1038/nature12862 · Cited by 896 · cited 1×
“Interestingly, Schoggins and colleagues observed that cGAS exerted a broad inhibition of both DNA and RNA virus families independent of the canonical STAT1-based signaling pathway (22).”
BackgroundPersistent LCMV infection is controlled by blockade of type I interferon signaling
Teijaro, J. R., Ng, C., Lee, A. M., Sullivan, B. M., Sheehan, K. C. F., Welch, M., Schreiber, R. D., Carlos de la Torre, J., & Oldstone, M. B. A. (2013) · Science · doi:10.1126/science.1235214 · Cited by 755 · cited 7×
“In contrast to their antiviral and stimulatory roles in acute viral infections, our group and Michael Oldstone’s group identified IFN-I signaling during chronic LCMV infection to drive many of the immune dysfunctions associated with viral persistence (118, 119).”
BackgroundResultInfluentialSTING agonist formulated cancer vaccines can cure established tumors resistant to PD-1 blockade
Fu, J., Kanne, D. B., Leong, M., Glickman, L. H., McWhirter, S. M., Lemmens, E., Mechette, K., Leong, J. J., Lauer, P., Liu, W., et al. (2015) · Science Translational Medicine · doi:10.1126/scitranslmed.aaa4306 · Cited by 720
Blockade of chronic type I interferon signaling to control persistent LCMV infection
Wilson, E. B., Yamada, D. H., Elsaesser, H., Herskovitz, J., Deng, J., Cheng, G., Aronow, B. J., Karp, C. L., & Brooks, D. G. (2013) · Science · doi:10.1126/science.1235208 · Cited by 709 · cited 10×
“However, in persistent infections, this beneficial, heightened antiviral response is short-lived as the systemic IFN-I burst is reduced to levels observed in naïve hosts, even though the viral burden remains elevated (7, 118).”
BackgroundResultInfluentialSelf-citationTBK-1 Promotes Autophagy-Mediated Antimicrobial Defense by Controlling Autophagosome Maturation
Pilli, M., Arko-Mensah, J., Ponpuak, M., Roberts, E., Master, S., Mandell, M. A., Dupont, N., Ornatowski, W., Jiang, S., Bradfute, S. B., et al. (2012) · Immunity · doi:10.1016/j.immuni.2012.04.015 · Cited by 655
Ex Vivo Profiling of PD-1 Blockade Using Organotypic Tumor Spheroids
Jenkins, R. W., Aref, A. R., Lizotte, P. H., Ivanova, E., Stinson, S., Zhou, C. W., Bowden, M., Deng, J., Liu, H., Miao, D., et al. (2018) · Cancer Discovery · doi:10.1158/2159-8290.cd-17-0833 · Cited by 594
PARP inhibition elicits STING-dependent antitumor immunity in brca1-deficient ovarian cancer
Ding, L., Kim, H.-J., Wang, Q., Kearns, M., Jiang, T., Ohlson, C. E., Li, B. B., Xie, S., Liu, J. F., Stover, E. H., et al. (2018) · Cell Reports · doi:10.1016/j.celrep.2018.11.054 · Cited by 572 · cited 1×
“Interestingly, the cGASSTING axis also plays important roles in inducing IFN-I signaling in cancers, and can be triggered by cancer therapies such as radiation therapy and inhibitors of the DNA damage pathway (24, 25).”
BackgroundComplex modulation of cell type-specific signaling in response to type I interferons
van Boxel-Dezaire, A. H. H., Rani, M. R. S., & Stark, G. R. (2006) · Immunity · doi:10.1016/j.immuni.2006.08.014 · Cited by 530 · cited 4×
“In contrast, signaling through STATs 3 and 5 generates antiapoptotic CD4 T cell responses, and is frequently observed in low amounts of STAT1 (50).”
BackgroundInfluentialThe interferon regulatory factor, IRF5, is a central mediator of toll-like receptor 7 signaling
Schoenemeyer, A., Barnes, B. J., Mancl, M. E., Latz, E., Goutagny, N., Pitha, P. M., Fitzgerald, K. A., & Golenbock, D. T. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.m412584200 · Cited by 411
Chistiakov, D. A., Myasoedova, V. A., Revin, V. V., Orekhov, A. N., & Bobryshev, Y. V. (2018) · Immunobiology · doi:10.1016/j.imbio.2017.10.005 · Cited by 311 · cited 1×
“In addition, unlike IRFs 1, 5 and 8, which are associated with polarization towards M1 macrophage phenotype, IRF4 is involved in skewing towards the anti-inflammatory M2 phenotype (80).”
BackgroundLazear, H. M., Lancaster, A., Wilkins, C., Suthar, M. S., Huang, A., Vick, S. C., Clepper, L., Thackray, L., Brassil, M. M., Virgin, H. W., et al. (2013) · PLoS Pathogens · doi:10.1371/journal.ppat.1003118 · Cited by 296 · cited 1×
“It has also been suggested that IRF5 may utilize the MAVS adaptor to induce IFN-I responses in some subsets of dendritic cells (15).”
BackgroundFujii, Y., Shimizu, T., Kusumoto, M., Kyogoku, Y., Taniguchi, T., & Hakoshima, T. (1999) · The EMBO Journal · doi:10.1093/emboj/18.18.5028 · Cited by 223
Bovolenta, C., Driggers, P. H., Marks, M. S., Medin, J. A., Politis, A. D., Vogel, S. N., Levy, D. E., Sakaguchi, K., Appella, E., & Coligan, J. E. (1994) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.91.11.5046 · Cited by 167
Regulation of T-cell activation and migration by the kinase TBK1 during neuroinflammation
Yu, J., Zhou, X., Chang, M., Nakaya, M., Chang, J.-H., Xiao, Y., William Lindsey, J., Dorta-Estremera, S., Cao, W., Zal, A., et al. (2015) · Nature Communications · doi:10.1038/ncomms7074 · Cited by 118
Sharf, R., Azriel, A., Lejbkowicz, F., Winograd, S. S., Ehrlich, R., & Levi, B.-Z. (1995) · Journal of Biological Chemistry · doi:10.1074/jbc.270.22.13063 · Cited by 100 · cited 1×
“With a weaker binding affinity to target ISREs, IRF8 works in concert with IRF1 and IRF2 to obtain optimal binding affinities (67).”
BackgroundStructural basis of STAT2 recognition by IRF9 reveals molecular insights into ISGF3 function
Rengachari, S., Groiss, S., Devos, J. M., Caron, E., Grandvaux, N., & Panne, D. (2018) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1718426115 · Cited by 91
Xiao, Y., Zou, Q., Xie, X., Liu, T., Li, H. S., Jie, Z., Jin, J., Hu, H., Manyam, G., Zhang, L., et al. (2017) · Journal of Experimental Medicine · doi:10.1084/jem.20161524 · Cited by 87
Cited by
Toll-like receptor 4 (TLR4) inhibitors: Current research and prospective
Zhang, Y., Liang, X., Bao, X., Xiao, W., & Chen, G. (2022) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2022.114291 · Cited by 299
Toll-like receptor 4: A potential therapeutic target for multiple human diseases
Wei, J., Zhang, Y., Li, H., Wang, F., & Yao, S. (2023) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2023.115338 · Cited by 121
Impact of Age-, Cancer- and Treatment-Driven Inflammation on T Cell Function and Immunotherapy
Quinn, K. M., Kartikasari, A. E. R., Cooke, R. E., Koldej, R. M., Ritchie, D. S., & Plebanski, M. (2020) · Journal of Leukocyte Biology · doi:10.1002/jlb.5mr0520-466r · Cited by 31
Nennig, K., Murthy, S., Maloney, S., Shaw, T. M., Sharobim, M., Matkovic, E., Fadiran, S., Larsen, M., Ramuta, M. D., Kim, A. S., et al. (2024) · PLOS Pathogens · doi:10.1371/journal.ppat.1012436 · Cited by 2
Metadata
- Authors
- Lukhele, S., Boukhaled, G. M., & Brooks, D. G.
- Venue
- Seminars in Immunology
- Publisher
- Elsevier BV
- Published
- 2019-06
- Volume
- 43
- Pages
- 101277
- ISSN
- 1044-5323 (ISSN-L)
- OpenAlex
- W2947489447
- Cited by
- 165
- References
- 35
- FWCI
- 3.04
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.